FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug
The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.
ARCHIVED · 1 LEFT · 0 CENTER · 1 RIGHT · Nov 16, 12:56 AM
One headline states the FDA "Doesn't Approve" the drug, while the other uses the stronger term "Rejects" and adds that the drug was "Closely Watched."
30-SECOND READ
WORDING GAP
2 sources · 2 bias buckets · Low confidence
Different Spin. The left frames it as "F.D.A. Rejects Closely Watched Lung Cancer Drug From China". The right frames it as "FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug".
SOURCE MAP TIMELINE
Nov 15, 7:34 PM: Investor's Business Daily joined the source map.
Nov 15, 8:33 PM: New York Times - Business joined the source map.
Now: Wording Gap is 45/99 and story health is developing · 2 sources · 2 buckets.
ARCHIVED SOURCES
The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.
The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.